San Diego, CA, Oct 23, 2023 (GLOBE NEWSWIRE) — Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, announces that it has signed a provider contract with Contigo Health ConfigureNetTM provider network. This commercial agreement will make Mindera’s psoriasis biologic prediction test, Mind.Px, available to clients and their health plan members served by clients of Contigo Health.
“This significant agreement represents another meaningful milestone in the continued growth and acceptance of tests that enable the most therapeutic and cost-effective decisions,” said Ron Rocca, CEO and President of Mindera Health. “Use of Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment and provide physicians, patients, and payers with a powerful tool to guide the individual patient to an efficacious drug…